A Call for an Evidence-Based Approach to the Heart Team for Patients With Severe Aortic Stenosis  by Coylewright, Megan et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y VO L . 6 5 , N O . 1 4 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 2 . 0 3 3REVIEW TOPIC OF THE WEEKA Call for an Evidence-Based Approach
to the Heart Team for Patients With
Severe Aortic Stenosis
Megan Coylewright, MD, MPH,* Michael J. Mack, MD,y David R. Holmes, JR, MD,z Patrick T. O’Gara, MDxABSTRACTFro
Dis
Cli
Ma
P.K
Lis
Yo
MaApplication of a Heart Team approach is now a central concept in the care of patients with severe aortic stenosis. It has
Class I recommendations from American and European professional societies and is required for reimbursement for
transcatheter aortic valve replacement in the United States. The rationale for changing traditional practice models is to
improve patient selection, procedural planning, and management of patients at high or prohibitive surgical risk, thus
improving outcomes. Although the concept is intuitive, a clear deﬁnition of the Heart Team, and data supporting its
effectiveness, are lacking. Other specialties, including oncology, provide a precedent for investigation of the use of a
multidisciplinary team and its impact on patient care. We highlight the need for clear deﬁnitions and shared metrics to
advance our understanding of an optimal Heart Team approach, focusing on patient, clinician, and health system
outcomes. (J Am Coll Cardiol 2015;65:1472–80) © 2015 by the American College of Cardiology Foundation.T he application of a Heart Team approach isnow a central concept in the care of patientswith severe aortic stenosis (AS). It has a Class I
recommendation (Level of Evidence: C) from both
American and European professional societies and is
required in the United States for reimbursement for
transcatheter aortic valve replacement (TAVR) (1–3).
Although the concept of using a multidisciplinary
team for clinical decision making for complex patients
seems intuitively obvious, a clear deﬁnition of the
Heart Team and data to support its effectiveness are
lacking.
In its current form, the Heart Team primarily fo-
cuses on the partnership of a cardiovascular surgeon
and an interventional cardiologist, emulating 2 large
randomized trials: SYNTAX (Synergy Between PCI
With Taxus and Cardiac Surgery) and PARTNER
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AB BR E V I A T I O N S
AND ACRONYM S
AS = aortic stenosis
AVR = aortic valve
replacement
TAVR = transcatheter aortic
valve replacement
TVT = transcatheter
valve therapy
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1473process, it is suggested that patient, clinician, and
health system outcomes may improve, such as opti-
mization of patient selection, improved skill sets of
clinicians, increased procedural success, and reduced
hospital readmissions (8,10,11). An additional goal is
to deliver more patient-centered care, taking into
account patient preferences and values through
processes such as shared decision making (1,2,12).
Ideally, the use of a Heart Team represents more
effective use of health care resources and thus higher
value health care. However, without information
on the cost of implementation, as well as changes
in health care outcomes, attainment of these goals
cannot be conﬁrmed (Central Illustration).
It appears that the “Heart Team approach . has
become mandatory” as a health care delivery model
for high risk, costly procedures, such as aortic valve
replacement (AVR) (9). However, there are many ex-
amples within medicine of initially attractive con-
cepts, which, when studied rigorously, are found not to
be effective (13). We highlight the need for research to
clearly deﬁne the Heart Team and metrics by which it
can be assessed in order to advance our understanding
of the optimal care delivery model for patients with
severe AS. Only this, in combination with sharing of
best practices (14), can lead to the outcomes widely
proclaimed to result from a Heart Team approach. The
large investment in the Heart Team, and broad rec-
ommendations for its widespread deployment, makes
this health services research important.
ORIGINS OF THE HEART TEAM CONCEPT
AND CURRENT MODELS
The Heart Team is not a new concept for clinicians
caring for patients with valvular heart disease.
Dr. Robert Frye, of the Mayo Clinic, described the
explicit instructions he received as a young staff
cardiologist in the 1950s when evaluating patients for
heart surgery: “It is important that you personally
introduce your patient to the surgeon” (R. Frye,
March 2014). Surgeons would meet with cardiologists
outside patient rooms, discuss the case, and then the
2 clinicians would walk in together as a matter of
“good conduct” (R. Frye, March 2014). Similar prac-
tices existed in the early coronary angioplasty
experience with surgeons and interventionalists
viewing coronary angiograms together and partnering
in clinical decision making. However, with the
increasing pace of clinical practice over time and
experience, these traditions are often abandoned.
Instead of in-person consultations, physicians often
communicate by phone, e-mail, or indirectly through
asynchronous review of the medical record.The Heart Team, in the contemporary
sense, is often cited as originating from 2
randomized trials comparing percutaneous
and surgical strategies in coronary artery
disease and AS, respectively: SYNTAX (4) and
PARTNER (5,6). In these trials, a Heart Team
was used for selection of appropriate trial
patients during eligibility screening. The tri-
als did not, however, test the effectiveness of
this multidisciplinary approach on clinical
outcomes. The Heart Team in these research models,
as reﬂected in an expert consensus document on
TAVR (15), was composed of an interventional cardi-
ologist and cardiovascular surgeon. The expert
consensus document goes further to describe how a
Heart Team ought to behave, demonstrating “mutual
trust and commitment” and the ability “to work as a
group” (15).
The reimbursement requirement for a Heart Team
approach has signiﬁcantly inﬂuenced broad imple-
mentation of this practice. This began as the result of
early stakeholder conversations, in which how the
team members, namely the interventional cardiolo-
gist and cardiovascular surgeon, would be reim-
bursed for a shared procedure was debated. Given
concerns regarding discrepancies between payments
for “cognitive” work versus “procedural” work, a
compromise requiring both clinicians to be present
during valve placement, and thus be eligible for
payment, was reached.
The Heart Team deﬁnition was broadened by the
Centers for Medicare and Medicaid Services within
the National Coverage Determination to embody
“collaboration and dedication across medical spe-
cialties to offer optimal patient-centered care” (3).
The speciﬁc focus on a cardiovascular surgeon and
interventional cardiologist with a requirement to
“jointly participate” during the procedure remained.
However, it was also suggested to include other
members: “echocardiographers, imaging specialists,
heart failure specialists, cardiac anesthesiologists,
intensivists, nurses, and social workers” (3).
Similarly, the research literature describes the
Heart Team as an interventionalist and surgeon
simultaneously present during the TAVR procedure
itself, often with descriptions of the 2 clinicians
working collaboratively (Figure 1) (16). How this
relationship is unique from earlier partnerships
across specialties, such as between an echocardiog-
rapher and surgeon during surgical valve replace-
ment, is not clear. “Heart Team” may also be used
to describe the entire multidisciplinary team involved
in the care of high-risk, elderly patients in both
pre-procedural planning and post-procedural care
CENTRAL ILLUSTRATION The Heart Team Approach for Patients With Severe Aortic Stenosis: Concerns and Recommendations
Improved patient outcomes
•  Improved patient knowledge and satisfaction
•  Incorporation of patient preferences through 
shared decision making
•  Increased quality of life, improved survival
Improved clinican outcomes
•  Improved skill sets 
•  Increased job satisfaction
Improved health system outcomes
More effective utilization of health care 
resources, leading to increased value
Gather common metrics on patient outcomes
Follow patient-centered outcomes when 
assessing iterative changes to Heart Team 
approach (patient knowledge, satisfaction, 
participation in shared decision making)
Gather common metrics on clinician outcomes
•  Measure workplace satisfaction
•  Describe cross-training
•  Document outcomes related to patient-
centered care delivery
Gather common metrics 
on health system outcomes
Document length of stay, readmission rates, 
guideline adherence and variability in 
procedural selection with Heart Team 
interventions 
Unclear “Heart Team” definition
•  Current definition of “Heart Team” ranges from 
two clinicians to the large, diverse collection of 
multidisciplinary professionals involved in 
high-risk care
•  Clinical context of focus for study of “Heart 
Team” poorly defined (i.e., patient selection
process, procedural requirements, specifics of 
inpatient care)
Concept
Utilizing a multidisciplinary “Heart Team” for 
complex patients with severe aortic stenosis 
leads to improved outcomes for patients, 
clinicians, and health systems
Unproven patient outcomes
•  No documentation of improvement in clinical 
outcomes with Heart Team approach 
•  Relationship between patient-centered outcomes 
and Heart Team approach not well understood
(i.e., patient satisfaction, knowledge, quality of  
•  Shared decision making is widely recommended 
but rarely implemented systematically
Unproven clinician outcomes 
•  Prior survey research on multidisciplinary teams 
shows increase in job satisfaction
•  Anecdotal evidence of dysfunctional team 
dynamics and increased workplace stress
•  Minimal data on use of shared decision making
Unproven health system outcomes
Broad recommendations exist for Heart Team 
implementation without understanding of costs, 
benefits, and unintended consequences
Utilize clear, common definitions
•  Heart Team: interventional cardiologist 
and cardiovascular surgeon working in 
concert with other specialists and 
patient/family
•  Roles of team members require accurate 
description for study (i.e., “TAVR 
coordinator”)
•  Delineation of clinical context necessary 
CURRENT CONCERNS
POTENTIAL BENEFITS 
OF HEART TEAM APPROACH RECOMMENDATIONS
Coylewright, M. et al. J Am Coll Cardiol. 2015; 65(14):1472–80.
life)
The Heart Team approach requires study to validate potential improvements in patient, clinician, and health system outcomes, as well as cost, compared with other
health care delivery models. Clear deﬁnitions and common metrics to measure outcomes will contribute to a greater understanding of best practices. TAVR ¼ trans-
catheter aortic valve replacement.
Coylewright et al. J A C C V O L . 6 5 , N O . 1 4 , 2 0 1 5
A Heart Team for Aortic Stenosis Patients A P R I L 1 4 , 2 0 1 5 : 1 4 7 2 – 8 0
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eral cardiology, imaging, neurology, pulmonology,
anesthesia, geriatrics, palliative care, social work,
information technology, administration, and, now,
ﬁnance (17). Thus, current deﬁnitions range from 2
clinicians to a large, diverse collection of multidisci-
plinary professionals, making identiﬁcation of best
practices for Heart Teams more challenging.
Delineating how the concept of the novel Heart
Team differs from current models of care is essential
for documenting a change in outcomes and the
resultant cost or savings of innovations in care de-
livery with new processes or additional staff. For
example, most centers with a designated TAVR pro-
gram invest in a TAVR coordinator position, often
held by a seasoned, high-level nurse, an advancedpractice nurse, or a physician assistant. At high-
volume institutions, this role may be ﬁlled by as
many as 3 people. This person often organizes patient
testing; provides initial assessment, including history
and physical examination; presents patients to the
Heart Team physicians; and coordinates care in the
outpatient and inpatient settings. These delegated
activities may reduce the preparatory time required
by other clinicians and free them for additional tasks,
although speciﬁc data are lacking. Itemization of
salary and beneﬁts, ofﬁce space, and additional
equipment for this role may not be included in the
overall cost assessment of a TAVR program. Further
investments unique to a Heart Team model may
include the creation of joint clinics, in which inter-
ventional cardiologists and cardiovascular surgeons
FIGURE 1 Heart Team, Including Interventional Cardiology
and Cardiovascular Surgery
The Heart Team, as deﬁned by the Centers for Medicare and
Medicaid Services within the National Coverage Determination
for transcatheter aortic valve replacement, embodies “collabo-
ration and dedication across medical specialties to offer optimal
patient-centered care” (3), with a requirement that the cardio-
vascular surgeon and interventional cardiologist jointly partici-
pate during the procedure.
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1475see patients at the same time; Heart Team meetings
involving additional staff including anesthesiolo-
gists, imaging specialists, and others, during which
a varying number of patients are reviewed in detail;
new procedural space to facilitate collaboration,
such as a hybrid operating room; and additional
infrastructure, including specialized data managers,
schedulers, and administrators.
Interestingly, current sentiment suggests that care
is suboptimal without a Heart Team. However, pre-
vious studies comparable to SYNTAX, such as BARI
(Bypass Angioplasty Revascularization Investigation),
relied on 1 “responsible physician” to make the choice
of revascularization with good outcomes (18). During
the initial study introduction, it was not uncommon
for surgeons to come to the catheterization laboratory
to discuss suitability for trial entry, but as the trial
continued, physicians increasingly made decisions
alone (R. Frye, March 2014). Comparative effective-
ness observational research in patients with coronary
artery disease demonstrated that current practices,
most without formal Heart Teams, successfully select
treatment strategies leading to outcomes similar to
those seen in clinical trials using multidisciplinary
screening teams (19).
Recent publications, including those focusing on
coronary revascularization, suggest that the Heart
Team approach may positively impact adherence
to guideline-directed therapy, encourage the incor-
poration of patient values and preferences throughthe use of shared decision making, and improve
procedural outcomes (8,20). There is recognition,
however, that there are no randomized trials to
support this approach (21); rather, studies describe
outcomes of a multidisciplinary program without
a comparator (11,22). One of the few studies investi-
gating a speciﬁc Heart Team intervention compared a
multidisciplinary clinic including surgeons and
interventionalists to a multidisciplinary teammeeting
following a visit to a sole clinician. Signiﬁcant differ-
ences were seen, with faster decision times and a
greater “turn-down rate” for TAVR with the multi-
disciplinary clinic (23).
To identify areas for improvement that may be
addressed by new models of care, it will be important
to assess baseline data on the care that patients with
AS receive. National initiatives, such as the American
College of Cardiology’s Championing Care for the
Patient with Aortic Stenosis, may provide such data
(24). Existing registries for patients receiving trans-
catheter valve therapy, such as the TVT (Trans-
catheter Valve Therapy) registry (25) or the FRANCE-2
(French Aortic National CoreValve and Edwards)
registry (26), provide outcome data, but do not
include data on health care delivery models, thus
making it challenging to link outcomes to speciﬁc
models of care retrospectively. However, these may
be rich data sources for pre-observational and post-
observational studies.
OUTCOME MEASURES: EXAMPLES FROM
CARDIOLOGY AND ONCOLOGY
Multidisciplinary teams designed to work with com-
plex patients facing multiple therapeutic choices
have a longer history in the ﬁelds of advanced heart
failure and oncology. Research on the role of multi-
disciplinary teams for heart failure patients has pri-
marily focused on post-discharge care by delegated
staff to reduce readmission rates and mortality, with
some evidence of effectiveness. A recent Cochrane
Review summarizing published reports on multidis-
ciplinary models of heart failure management iden-
tiﬁed only 2 studies with a comparator group.
Outcome measures included the following: death;
hospital readmission and length of stay; event-free
survival; and quality of life (27). Although there was
no difference in mortality, hospital readmission and
length of stay were reduced with multidisciplinary
post-discharge management compared with usual
care (28,29).
There is a larger body of research on the role
of multidisciplinary teams in oncology, highlighting
the importance of the “multidisciplinary cancer
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conference (30). There are professional recommen-
dations for the presence of such teams: the Com-
mission on Cancer accredits cancer programs and
highlights the need for a multidisciplinary team
approach, with teams including “diagnosticians and
pathologists, surgeons, radiation oncologists, and
medical oncologists” (31). The beneﬁts of the team-
based approach and measurable outcomes include
the following: timeliness of treatment; continuity of
care and communication with referring clinicians;
collection of data for research; adherence to clinical
guidelines; effective use of resources; and improve-
ment in workplace satisfaction through opportu-
nities for professional development (32,33). There
are also data on improved survival in colorectal,
esophageal, and head and neck cancer patients with
the use of multidisciplinary teams (30). The largest
study demonstrated a relative 11% improvement
in survival for women with breast cancer managed
by a multidisciplinary team compared with usual
care (34).
Notably, both patient and clinician experiences
vary when multidisciplinary teams are imple-
mented. Whereas patient satisfaction may increase,
discrepancies may remain between clinician deci-
sion making and acceptance of a treatment re-
commendation due to patient preference for an
alternative therapy. There are also limited data on
the impact of implementing a multidisciplinary team
approach on clinicians’ professional satisfaction:
previous survey research suggested increased job
satisfaction, whereas anecdotal evidence exists of
dysfunctional team dynamics leading to stressful
interactions (32).
The actual costs of health care system in-
terventions, such as a multidisciplinary team ap-
proach, remain difﬁcult to determine, with minimal
data on which to base ﬁrm conclusions (35). Team
meetings may be among the larger consumers of
resources for the Heart Team, as compared to usual
care, and the complex measure of clinician time to
prepare for and attend meetings must be considered.
Oncology team meetings in the United Kingdom
were estimated to cost $100,000 per team per year
for staff preparation and attendance time alone (32).
However, there is also evidence suggesting that
team-based assessment of complex patients may
save time for individual clinicians, thus lowering
costs (36).
The ﬁelds of advanced heart failure and on-
cology thus set the stage for selection of outcome
measures that might aid in assessment of the effec-
tiveness of a multidisciplinary Heart Team model.Measurable goals can be organized into 3 categories:
patient-centered outcomes; clinician outcomes; and
health system outcomes (Table 1). Improving
patient-centered care, a laudable goal that many
trace to the Institute of Medicine (37), can be fol-
lowed by measuring the following: improvement in
patient knowledge; reduction in decisional conﬂict
(a measure of the degree of uncertainty related
to decision making); patient satisfaction; involve-
ment in shared decision making; and improvement
in patient-deﬁned outcomes, such as quality of
life. Identiﬁcation of existing data sources will
be critical (38). Clinician outcomes may include
greater knowledge; improved workplace satisfaction,
particularly as related to a sense of trust, commit-
ment, and ability to work as a team; participation
in shared decision making; and improved procedural
skill sets. Health system outcomes that reﬂect
effective care delivery by Heart Teams may include
the following: reduction in geographic variability
in access to care and outcomes through measures of
improvement in overuse and underuse of trans-
catheter valve therapies; reduced time to decision;
increased adherence to guideline-directed therapy;
lower readmission rates; shorter lengths of stay
with reduced intensive care unit time; lower
costs; and better relationships with referring clini-
cians (improved communication across the care
spectrum). Potential metrics to measure progress
toward these goals are noted, with a focus on
using existing databases when possible (Table 2)
(39–42).
With common deﬁnitions and metrics, it may be
possible to show that Heart Teams both enhance
quality and reduce costs, leading to increased value.
Increased quality at lower cost, along with improving
the health of populations, constitutes the “Triple
Aim” espoused by the Institute for Health Improve-
ment (43). Careful study and implementation of the
Heart Team approach may lead to reduced waste
through improvement in care delivery, including
safer procedures; increased care coordination, with
less need for repeat tests and prolonged physician
involvement; and fewer procedures that do not match
patient preferences and values (less overtreatment)
(44). Alternatively, once wasteful practices are iden-
tiﬁed, speciﬁc aspects of existing Heart Team models
may be eliminated. The impetus for investigating the
utility of Heart Team interventions stems from the
need to demonstrate value in the changing reim-
bursement environment, in part by documenting
improvement in care delivery and related outcomes
in a quality “report card.” Objective demonstrations
of this sort will become increasingly important in
TABLE 1 Potential Outcomes of Effective Heart Team Interventions
Patient Clinician Health System
Improved knowledge x x
Reduced decisional conﬂict x
Greater satisfaction (with care delivery process) x x
Involvement in shared decision making x x
Improved quality of life (functional status [patient]
or workplace [clinician])
x x
Expanded clinical and procedural skill set x
Reduction in variability both in access and outcome x
Greater adherence to guidelines x
Lower readmission rates x
Shorter length of stay x
Faster time to decision x
Lower cost x
Improved care coordination and communication x
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local and national levels.
NEXT STEPS AND POTENTIAL BARRIERS
To study the effectiveness of varying Heart Team
approaches for patients with severe AS, we suggest
deﬁning the Heart Team as an interventional cardi-
ologist and a cardiovascular surgeon. This core team
works in concert with other specialists, and with the
patient and his or her family. Speciﬁc description of
the team members and their roles will be essential in
study methodology: for example, the role of a “TAVR
coordinator” varies across institutions, but most
often serves a primary role in program development
and patient care, with a sole focus on this patient
subset. We also recommend clariﬁcation of the in-
vestigation’s clinical context: in the evaluation for
AVR (for patients at high or prohibitive risk for sur-
gical AVR); its resultant performance (i.e., in the
operating room or cardiac catheterization laboratory
or hybrid operating room); post-procedure; or in
follow-up for patients selecting medical therapy.
Patient selection by the Heart Team may occur eitherTABLE 2 Metrics of Effective Heart Team Interventions
Desired Outcome Potential Metric
Improved knowledge Patient knowledge, clinician knowledge
options, pertinent clinical work-up, r
Reduced decisional conﬂict Patient decisional conﬂict
Greater satisfaction Patient satisfaction, clinician satisfaction
Involvement in shared
decision making
Level of patient engagement by the clin
shared decision making
Improved quality of life Kansas City Cardiomyopathy Questionna
Expanded clinical and
procedural skill set
Metrics may include reported comfort w
percutaneous access, crossing aortic
placing patients on peripheral cardio
responding to iliac artery emergencie
Reduction in variability Relative rates of TAVR, SAVR, medical th
eligible patients with severe aortic st
high or prohibitive surgical risk; appr
(transfemoral, etc.)
Greater adherence to
guidelines
Discharge medications, medications at 3
1 yr, follow-up of patients deferred f
Lower readmission rate Readmission rates following TAVR, SAVR
BAV for palliation
Faster time to decision Time from initial assessment to decision
SAVR, medical therapy), time to trea
Lower cost Measurable cost (testing, procedure, LO
and physician extender time (within
of scheduled appointments, meeting
Improved care coordination Referring physician feedback, reduction
testing, reduction in time delays
AVR ¼ aortic valve replacement; BAV ¼ balloon aortic valvuloplasty; CAHPS ¼ Consumer
Involvement; SAVR ¼ surgical aortic valve replacement; STS ¼ Society of Thoracic Surgin separate clinics (e.g., cardiology valve clinic and
surgery clinic) or in 1 clinic with both procedural
clinicians present (e.g., TAVR clinic). Communica-
tion methods among clinicians regarding treatment
selection and procedural planning may be compared
in the following ways: in-person immediatelyExamples of How Measured or Reported
(i.e., available
isks, and beneﬁts)
Survey, percentage correct
Survey using decisional conﬂict scale, based on
the Ottawa Shared Decision Making Framework (39)
Survey (use of existing ambulatory care surveys,
i.e., CAHPS)
ician in Review of video or audiotaped clinical visits by trained
observers using OPTION score (40), patient reporting
using CollaboRATE (41), surveys
ire (42) TVT registry (before intervention, 30 days, 1 yr); surveys
for SAVR, medical therapy, and for clinicians
ith
valve, wire skills,
pulmonary bypass,
s
Clinician survey
erapy for
enosis with
oach
TVT registry, STS registry, chart review for medical therapy
patients, local rates of referral to palliative care
0 days and
or AVR
TVT registry, STS registry, local practice surveys
(i.e., echocardiography follow-up)
, or TVT registry, STS registry, local chart review
(TAVR,
tment
Local chart review or surveys
S), physician
and outside
s, and procedures)
Survey, observation of clinician time used for care of
patients outside of clinic or procedure (shadowing)
in duplicate Survey to referring clinicians, survey of tertiary clinicians
Assessment of Healthcare Providers and Systems; LOS ¼ length of stay; OPTION¼ Observing Patient
eons; TAVR ¼ transcatheter aortic valve replacement; TVT ¼ transcatheter valve therapy.
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meeting; over the phone; or via indirect communi-
cation through asynchronous review of the medical
record. Transcatheter procedures performed by a
Heart Team will have both interventionalists and
surgeons present, along with other critical clinicians
including, but not limited to, imaging specialists,
anesthesiologists, and nursing; their numbers and
roles may differ and will lead to varying beneﬁts
and costs. Accurate descriptions will be needed to
delineate effects.
Identiﬁcation of a comparison group is important
for actionable conclusions, and sharing of best prac-
tices through quantitative “stories” will also be
necessary (14). Multiple study designs are applicable
to the care of patients with AS, including pre-/post
implementation of a speciﬁc Heart Team interven-
tion; observational studies between centers with and
without Heart Teams; randomized trials of a speciﬁc
Heart Team approach within centers (those who have
multiple teams) or between centers; and comparison
of decision making by individual physicians versus a
Heart Team (21). In order to assess both improve-
ments and unintended consequences, we recommend
that centers consider assessing their current models
of care before implementing a new Heart Team
approach or new innovations to their current Heart
Team model. Examples of innovations include insti-
tution of a Heart Valve clinic in which clinicians see
patients together; addition or removal of a Heart
Team meeting or TAVR coordinator in the work-up of
lower-risk patients; changing the number of team
members as experience grows; or use of a new loca-
tion for procedures (i.e., assessing impact of invest-
ment in a hybrid operating room). A notable challenge
to a pre-/post-intervention study design is rapid
evolution of TAVR technology. Contemporary com-
parison groups, rather than historical control subjects
alone, are critical. Recent reviews of multidisciplinary
team interventions in oncology highlight how het-
erogeneity in deﬁnitions and multiple confounding
variables make ﬁrm conclusions on beneﬁts and costs
challenging, requiring careful consideration in study
design (30).
Some reported Heart Team goals might, at times,
counter one another, such as adherence to guidelines
with simultaneous incorporation of patient pref-
erences if the 2 are incongruent. This provides
opportunities for research to further inform pro-
fessional society recommendations (45). Individu-
alizing care with a thoughtful, multidisciplinary
assessment involving the patient may lead to practice
outside of guideline recommendations; documenta-
tion of movement toward a more patient-centricapproach following changes in care delivery models
will be meaningful. The Centers for Medicare and
Medicaid Service’s National Coverage Determinations
will constrain some choices available to patients,
highlighting the need for ongoing assessment by a
knowledgeable team.
Although not widely implemented, shared decision
making is often mentioned among the Heart Team
goals as a means to elicit and include patient prefer-
ences in decisions (46). With current models of care,
the manner in which clinicians present information
may affect patient decision making regarding invasive
procedures (47), and patient preferences are
commonly misinterpreted by clinicians (48). Shared
decision making may limit clinician bias favoring a
mortality beneﬁt over other patient-centered out-
comes and assist in communicating choices that reﬂect
patient preferences regarding the decision to undergo
AVR (49). It may also address patient misconceptions,
including that less invasive therapies are always bet-
ter; evidence regarding the impact of shared decision
making on treatment choice is limited, however (50).
Knowledge alone is not sufﬁcient for patients to
participate in shared decision making; rather, an
explicit invitation must exist for patients to feel
comfortable expressing informed preferences (51).
Further research is clearly needed to respond to the call
in the most recent American Heart Association/Amer-
ican College of Cardiology Valvular Heart Disease
Guidelines, recommending that Heart Teams ensure
that patient “expectations can be met as fully as
possible using a shared decision-making approach” (1).
Two unique opportunities exist for assessment of
the current health care delivery model for patients
with a choice of transcatheter versus surgical valve
therapy. Experienced centers are maturing with re-
gard to the knowledge base needed for patient evalu-
ation at the same time that transcatheter aortic valve
therapies are evolving to include intermediate-risk
patients. There may be less need for detailed proce-
dural planning by a Heart Team for lower-risk pa-
tients, making review of every patient in a formal
meeting superﬂuous. As the indications for TAVR
extend to intermediate-risk groups, there will be an
increasing need for shared decision making, given the
choice between 2 comparable options with clearly
different risks and beneﬁts, which will be contex-
tualized by patient values and preferences. Thus,
new models of the traditional weekly Heart Team
meeting will be needed, likely with increasing patient
involvement.
A second opportunity for assessment of the Heart
Team delivery model includes addition of other trans-
catheter therapies for structural heart disease, including
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1479mitral therapies (52,53), with centers beginning to study
the ﬁrst dedicated transcatheter mitral valve (54).
Adding new therapies will require thoughtful planning
on how each institution can best deploy resources.
Understanding the return on investment for compo-
nents of the Heart Team care delivery model including
the TAVR coordinator, joint clinics, and weekly Heart
Team meetings will inform care delivery for these
therapies, as well as future options that may include
more diverse team members (i.e., electrophysiologists
involved in left atrial appendage closure) (55).
Barriers to implementation and study of the Heart
Team include, but are not limited to, the following:
local hospital and clinician culture; physical location
of clinicians; schedules; ofﬁce space; support staff
(nurses/physician extenders/fellows); funding; and
leadership. A focus on incorporation of patients
and their families as part of the Heart Team through
shared decision making will require additional
skill sets. Finally, a continued focus on equitable
reimbursement for services provided by diverse
team members will be needed (20). Furthercommunication between centers regarding best
practices for Heart Team implementation should
occur and formal quality improvement publications
with speciﬁc details of delivery innovation are
welcome.
CONCLUSIONS
Wide-scale implementation of an intervention that
may affect patient outcomes, including redesign of
health care delivery, must be tested to validate
effectiveness. The recommendation for the use of a
Heart Team in the care of high or prohibitive surgical
risk patients with severe AS makes intuitive sense
and is ripe for investigation regarding its optimal
structure and impact on patient outcomes.
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